Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy VS Dr. Reddy's: Clash of the titans! - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 5, 2005

    Ranbaxy VS Dr. Reddy's: Clash of the titans!

    Domestic pharma heavyweights, Ranbaxy and Dr.Reddy's have been the pioneers in establishing a global presence and moving ahead of competition in new drug discovery in the domestic pharma industry. While both the companies have similar business models (in respect of focus on generics and new drug discovery), we take a look at how these companies compare against each other on certain parameters.

    Financial comparison
    (Rs m) Ranbaxy (CY04) Dr.Reddy's (FY05)
    Net sales 52,451 18,359
    Sales growth (4 year CAGR) 25.5% 4.0%
    Operating profit 10,005 784
    Operating profit margin (%) 18.4% 4.3%
    Net profit 6,986 330
    Net profit margin (%) 12.8% 1.8%
    Net profit growth (4 year CAGR) 70.6% -61.4%

    How do they compare?

    Revenues: Both Dr.Reddy's and Ranbaxy have aimed to establish a global footprint over the years. Also as far as international markets are concerned, both these companies have been focusing on the generic markets of the US and Europe as well as the semi-regulated markets of Russia, CIS and others. However, the similarity ends there. While US is the major growth driver for Ranbaxy contributing around 36% to total revenues (CY04), the contribution from this region to Dr.Reddy's revenues is only 16% (FY05). Having said that, lately the US region has dampened the revenues of both Ranbaxy (marginal 2% YoY growth in CY04) and Dr.Reddy's (down 28% YoY in FY05) on account of intense competition and severe price erosion.

    The geographical contribution to revenues has been different for both these companies. Indian markets are higher on Dr.Reddy's radar, which can be gauged by the fact that this region contributes 41% to its total revenues as compared to only 22% contribution to Ranbaxy's revenues. However, in absolute terms, Ranbaxy is ahead of Dr.Reddy's with Rs 8 bn in revenues from the domestic market as compared to the latter's revenues of Rs 7 bn, which suggests the fact that Ranbaxy has a stronger presence in the Indian pharma market.

    The contribution of exports to Ranbaxy's revenues (about 80%) stands higher than that of Dr. Reddy's (60%). While US has been the key revenue generator for Ranbaxy (regular and more balanced ANDA filings have led to growth), India and the Rest of World (ROW, including CIS, Russia and Brazil) has been the major contributor to Dr.Reddy's revenues. In fact, the 13% YoY growth in ROW revenues (branded formulations has boosted growth) in FY05 was the only silver lining in the cloud for Dr.Reddy's, which witnessed a decline in revenues in all the other regions.

    One must also note the fact that as far as the domestic pharma market is concerned, while the negative impact of VAT is already factored into Dr. Reddy's performance, the same will be reflected in Ranbaxy's performance in CY05.

    R&D: Both the companies have been pioneers in R&D in India. While Dr. Reddy's R&D spend accounts for 13% of revenues (more or less in line with the global trend), Ranbaxy's spend accounts for 6% of revenues, which it plans to increase steadily to 9% by CY07. The R&D efforts are directed towards new drug discovery research and generics. However, in Dr. Reddy's case, the R&D ratio is a little skewed owing to a drastic fall in revenues in FY05.

    As far as ANDA filings are concerned, Ranbaxy's strategy has been more stable than that of Dr. Reddy's. This is due to the fact that Dr. Reddy's has focused more on the highly risky strategy of Para IV filings, with a dismal success rate, the exception being that of 'fluoxetine axetil'. Ranbaxy, on the other hand, has also been focusing on Para II and Para III filings, which has ensured a steady revenue stream to the company.

    Operating margins: On the expenditure side, raw material costs (as a percentage of sales) have been lower for Dr. Reddy's. This can be attributed to a higher contribution from exports in Dr. Reddy's case as against Ranbaxy. The higher employee costs in case of Dr. Reddy's can be attributed to the mounting R&D expenditure and also increased activity on the ANDA front (especially Para IV). As far as the US generic market goes, Ranbaxy has a much stronger standing in the region. This is probably why Ranbaxy's selling and administrative expenses are lower compared to Dr. Reddy's. To sum up, rising R&D expenditure coupled with mounting legal costs had severely dented Dr.Reddy's profitability in FY05.

    Cost comparison
    (% of sales) Ranbaxy (CY04) Dr.Reddy's (FY05)
    Raw material costs 35.0% 32.8%
    R&D expenditure 6.2% 12.5%
    Employee costs 11.7% 16.0%
    Selling & administrative costs 28.7% 34.5%


    Currently, Dr.Reddy's is trading at a premium to Ranbaxy, which can be gauged by the fact that while the former is trading at a price to earnings multiple of 38.1 times our estimated FY08 earnings, Ranbaxy is trading at a price to earnings multiple of 13.1 times our estimated CY07 earnings. It must be noted that Dr.Reddy's lower EPS of 4.3 has led to the artificially high price to earnings multiple. Pricing pressure in the US markets is expected to plague both the companies in the current fiscal as well. However, as far as Dr. Reddy's is concerned, while we believe that the worst for the company is over and it is gradually trudging on the recovery path, the current valuations are rather rich. In the case of Ranbaxy, despite hiccups in CY05, we believe that patent expiries of some major blockbuster drugs will boost its performance in CY06 and CY07.Keeping that in mind, at the current juncture, we prefer Ranbaxy to Dr. Reddy's.



    Equitymaster requests your view! Post a comment on "Ranbaxy VS Dr. Reddy's: Clash of the titans!". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Apr 1, 2015 (Close)


    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks